Global genetic testing market is expected to reach USD 62,607,580.19 thousand by 2031 from USD 18,810,536.39 thousand in 2023, growing at a CAGR of 16.5% during the forecast period of 2024 to 2031. Market Segmentation Global Genetic Testing Market, By Type (Carrier Testing, Diagnostic Testing, New Born Screening, Predictive and Presymptomatic Testing, and Other Types), Technology (DNA sequencing, Polymerase Chain Reaction, Microarrays, Whole Genome Sequencing, Fluorescence In Situ Hybridization (FISH), and Others), Diseases (Rare Genetic Disorder, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Fragile X Syndrome, and Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers, Private Clinics, Laboratory Service Providers, and Private Laboratories), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031 Overview of Global Genetic Testing Market Dynamics Driver • Growing prevalence of genetic disorders Restrain • High cost of genetic testing Opportunity • Strategic initiatives by the key market player Market Players Some of the key market players for global genetic testing market are: • Thermo Fisher Scientific Inc. • Invitae Corporation • Bio-Rad Laboratories, Inc. • PerkinElmer Inc. • Illumina, Inc. • QIAGEN • F. Hoffmann-La Roche Ltd. • Fulgent Genetics • Myriad Genetics, Inc. • Abbott • Eurofins Scientific • Sorenson Genomics • BIO-HELIX • Biocartis • Cepheid (A subsidiary of Danaher) • PacBio • ELITechGroup • Genes2Me • Eugene Labs • Otogenetics • Mapmygenome • MedGenome • BioReference • Natera, Inc.

1 INTRODUCTION 68 1.1 OBJECTIVES OF THE STUDY 68 1.2 MARKET DEFINITION 68 1.3 OVERVIEW OF THE GLOBAL GENETIC TESTING MARKET 68 1.4 LIMITATIONS 70 1.5 MARKETS COVERED 70 2 MARKET SEGMENTATION 73 2.1 MARKETS COVERED 73 2.2 GEOGRAPHICAL SCOPE 74 2.3 YEARS CONSIDERED FOR THE STUDY 75 2.4 CURRENCY AND PRICING 75 2.5 DBMR TRIPOD DATA VALIDATION MODEL 76 2.6 TYPE LIFELINE CURVE 80 2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 81 2.8 DBMR MARKET POSITION GRID 82 2.9 MARKET APPLICATION COVERAGE GRID 83 2.10 VENDOR SHARE ANALYSIS 84 2.11 SECONDARY SOURCES 85 2.12 ASSUMPTIONS 85 3 EXECUTIVE SUMMARY 86 4 PREMIUM INSIGHTS 88 4.1 PESTAL ANALYSIS 91 4.2 PORTERS 5 FORCES 92 4.3 EPIDEMIOLOGY 93 5 GLOBAL GENETIC TESTING MARKET: REGULATIONS 94 6 MARKET OVERVIEW 96 6.1 DRIVERS 98 6.1.1 GROWING PREVALENCE OF GENETIC DISORDERS 98 6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 98 6.1.3 WIDE PRODUCT PORTFOLIO OFFERED BY A MAJOR PLAYER 99 6.1.4 INCREASE THE TREND TOWARD PERSONALIZED MEDICATION 99 6.2 RESTRAINTS 100 6.2.1 HIGH COST OF GENETIC TESTING 100 6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 101 6.3 OPPORTUNITIES 101 6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 101 6.3.2 TECHNOLOGICAL ADVANCEMENT IN THE FIELD OF GENETIC TESTING 102 6.3.3 INCREASING RESEARCH AND DEVELOPMENT FOR GENETIC TESTING 102 6.4 CHALLENGES 103 6.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM GENETIC TESTING 103 6.4.2 STRINGENT REGULATION POLICY FOR GENETIC TESTING 104 7 GLOBAL GENETIC TESTING MARKET, BY TYPE 105 7.1 OVERVIEW 106 7.2 DIAGNOSTIC TESTING 110 7.3 PRENATAL TESTING 110 7.3.1 NON-INVASIVE SCREENING 111 7.3.1.1 WHOLE GENOME SEQUENCING 112 7.3.1.2 COUNTING OF CFDNA FRAGMENTS 112 7.3.1.3 OTHERS 112 7.3.2 BY CONDITION 113 7.3.2.1 TRISOMY 21 113 7.3.2.2 KLINEFELTER SYNDROME 113 7.3.2.3 JACOBS SYNDROME 113 7.3.2.4 CYSTIC FIBROSIS 113 7.3.2.5 TURNER SYNDROME 114 7.3.2.6 TRISOMY 18 114 7.3.2.7 HEMOPHILIA 114 7.3.2.8 TRISOMY 13 114 7.3.2.9 MICRODELETION SYNDROME 114 7.3.2.10 FETAL GENDER 114 7.3.2.11 OTHERS 114 7.3.3 BY SCREENING TYPE 115 7.3.3.1 CARRIER SEQUENCING 115 7.3.3.2 SEQUENTIAL SEQUENCING 115 7.3.4 MATERNAL SERUM QUAD SCREENING 115 7.4 NEW-BORN SCREENING 116 7.4.1 SICKLE CELL DISEASE 116 7.4.2 CONGENITAL HYPOTHYROIDISM 117 7.4.3 PHENYLKETONURINA (PKU) 117 7.4.4 GALACTOSEMIA 117 7.4.5 MAPLE SYRUP URINE DISEASE 117 7.4.6 OTHERS 117 7.5 PREDICTIVE AND PRESYMPTOMATIC TESTING 117 7.6 CARRIER TESTING 118 7.6.1 MOLECULAR SCREENING TEST 118 7.6.2 BIOCHEMICAL SCREENING TEST 119 7.6.2.1 EXPANDED CARRIER SCREENING 119 7.6.2.2 PREDESIGNED PANEL TESTING 120 7.6.2.3 CUSTOM-MADE PANEL TESTING 120 7.6.2.4 TARGETED DISEASE CARRIER SCREENING 120 7.6.2.4.1 HEMATOLOGICAL CONDITIONS 120 7.6.2.4.2 PULMONARY CONDITIONS 121 7.6.2.4.3 NEUROLOGICAL CONDITIONS 121 7.6.2.4.4 OTHER CONDITIONS 121 7.7 OTHER TYPES 121 8 GLOBAL GENETIC TESTING MARKET, BY TECHNOLOGY 122 8.1 OVERVIEW 123 8.2 POLYMERASE CHAIN REACTION 126 8.2.1 REAL-TIME PCR (QPCR) 127 8.2.2 DIGITAL PCR (DPCR) 127 8.2.3 REVERSE TRANSCRIPTION PCR (RT-PCR) 127 8.2.4 HOT-START PCR 127 8.2.5 MULTIPLEX PCR 127 8.2.6 OTHER PCR 127 8.3 DNA SEQUENCING (NGS-BASED TESTING) 128 8.3.1 NEXT GENERATION SEQUENCING (NGS) 128 8.3.2 SANGER SEQUENCING (SINGLE GENE) 128 8.3.3 OTHER 129 8.4 WHOLE GENOME SEQUENCING 129 8.5 MICROARRAYS 129 8.5.1 DNA MICROARRAYS 130 8.5.2 PROTEIN MICROARRAYS 130 8.5.3 OTHER MICROARRAYS 130 8.6 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 130 8.7 OTHERS 131 9 GLOBAL GENETIC TESTING MARKET, BY DISEASES 132 9.1 OVERVIEW 133 9.2 CANCER 136 9.2.1 BREAST 137 9.2.2 COLON 137 9.2.3 LUNG 137 9.2.4 PROSTATE 137 9.2.5 OTHERS 137 9.3 SICKLE CELL ANEMIA 138 9.4 THALASSEMIA 138 9.5 RARE GENETIC DISORDER 139 9.5.1 TRISOMY 21 139 9.5.2 MONOSOMY X 139 9.5.3 TRISOMY 13 140 9.5.4 MICRODELETION SYNDROME 140 9.5.5 TRISOMY 18 140 9.5.6 OTHERS 140 9.6 FRAGILE X SYNDROME 140 9.7 DUCHENNE MUSCULAR DYSTROPHY 141 9.8 HUNTINGTON'S DISEASE 141 9.9 CYSTIC FIBROSIS 142 9.10 OTHERS 142 10 GLOBAL GENETIC TESTING MARKET, BY END USER 143 10.1 OVERVIEW 144 10.2 HOSPITALS 147 10.3 CLINICS 148 10.4 DIAGNOSTIC CENTERS 148 10.5 PRIVATE CLINICS 149 10.6 LABORATORY SERVICE PROVIDERS 149 10.7 PRIVATE LABORATORIES 150 11 GLOBAL GENETIC TESTING MARKET, BY REGION 151 11.1 OVERVIEW 152 11.2 NORTH AMERICA 155 11.2.1 U.S 165 11.2.2 CANADA 176 11.2.3 MEXICO 187 11.3 EUROPE 198 11.3.1 GERMANY 207 11.3.2 FRANCE 218 11.3.3 U.K 229 11.3.4 RUSSIA 240 11.3.5 ITALY 251 11.3.6 SPAIN 261 11.3.7 TURKEY 272 11.3.8 NETHERLANDS 283 11.3.9 SWITZERLAND 294 11.3.10 BELGIUM 305 11.3.11 REST OF EUROPE 316 11.4 ASIA-PACIFIC 317 11.4.1 CHINA 326 11.4.2 JAPAN 337 11.4.3 INDIA 348 11.4.4 SOUTH KOREA 359 11.4.5 AUSTRALIA 370 11.4.6 SINAGPORE 381 11.4.7 THAILAND 392 11.4.8 INDONESIA 403 11.4.9 PHILIPPINES 414 11.4.10 MALAYSIA 425 11.4.11 VIETNAM 436 11.4.12 REST OF ASIA-PACIFIC 447 11.5 SOUTH AMERICA 448 11.5.1 BRAZIL 456 11.5.2 ARGENTINA 466 11.5.3 REST OF SOUTH AMERICA 477 11.6 MIDDLE EAST AND AFRICA 478 11.6.1 SOUTH AFRICA 488 11.6.2 SAUDI ARABIA 499 11.6.3 U.A.E 510 11.6.4 ISRAEL 521 11.6.5 EGYPT 532 11.6.6 REST OF MIDDLE EAST AND AFRICA 543 12 GLOBAL GENETIC TESTING MARKET, COMPANY LANDSCAPE 544 12.1 COMPANY SHARE ANALYSIS: GLOBAL 544 13 NORTH AMERICA GENETIC TESTING MARKET, COMPANY LANDSCAPE 545 13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 545 14 EUROPE GENETIC TESTING MARKET, COMPANY LANDSCAPE 546 14.1 COMPANY SHARE ANALYSIS: EUROPE 546 15 ASIA-PACIFIC GENETIC TESTING MARKET, COMPANY LANDSCAPE 547 15.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 547 16 SWOT ANALYSIS 548 17 COMPANY PROFILES 549 17.1 ILLUMINA, INC 549 17.1.1 COMPANY SNAPSHOT 549 17.1.2 REVENUE ANALYSIS 549 17.1.3 COMPANY SHARE ANALYSIS 550 17.1.4 PRODUCT PORTFOLIO 550 17.1.5 RECENT DEVELOPMENT 551 17.2 CEPHEID 552 17.2.1 COMPANY SNAPSHOT 552 17.2.2 REVENUE ANALYSIS 552 17.2.3 COMPANY SHARE ANALYSIS 553 17.2.4 PRODUCT PORTFOLIO 553 17.2.5 RECENT DEVELOPMENT 553 17.3 FULGENT GENETICS 554 17.3.1 COMPANY SNAPSHOT 554 17.3.2 REVENUE ANALYSIS 554 17.3.3 COMPANY SHARE ANALYSIS 555 17.3.4 PRODUCT PORTFOLIO 555 17.3.5 RECENT DEVELOPMENT 556 17.4 PERKINELMER INC 557 17.4.1 COMPANY SNAPSHOT 557 17.4.2 REVENUE ANALYSIS 557 17.4.3 COMPANY SHARE ANALYSIS 558 17.4.4 PRODUCT PORTFOLIO 558 17.4.5 RECENT DEVELOPMENT 558 17.5 THERMO FISHER SCIENTIFIC INC 559 17.5.1 COMPANY SNAPSHOT 559 17.5.2 REVENUE ANALYSIS 559 17.5.3 COMPANY SHARE ANALYSIS 560 17.5.4 PRODUCT PORTFOLIO 560 17.5.5 RECENT DEVELOPMENT 561 17.5.5.1 COLLABORATION 561 17.6 BIOREFERENCE 562 17.6.1 COMPANY SNAPSHOT 562 17.6.2 REVENUE ANALYSIS 562 17.6.3 PRODUCT PORTFOLIO 563 17.6.4 RECENT DEVELOPMENT 563 17.7 ELITECHGROUP 564 17.7.1 COMPANY SNAPSHOT 564 17.7.2 PRODUCT PORTFOLIO 564 17.7.3 RECENT DEVELOPMENTS 565 17.8 EUROFINS SCIENTIFIC 566 17.8.1 COMPANY SNAPSHOT 566 17.8.2 REVENUE ANALYSIS 566 17.8.3 PRODUCT PORTFOLIO 567 17.8.4 RECENT DEVELOPMENT 567 17.9 INVITAE CORPORATION 568 17.9.1 COMPANY SNAPSHOT 568 17.9.2 REVENUE ANALYSIS 568 17.9.3 PRODUCT PORTFOLIO 569 17.9.4 RECENT DEVELOPMENTS 569 17.10 MYRIAD GENETICS 570 17.10.1 COMPANY SNAPSHOT 570 17.10.2 REVENUE ANALYSIS 570 17.10.3 PRODUCT PORTFOLIO 571 17.10.4 RECENT DEVELOPMENT 571 17.11 ABBOTT 572 17.11.1 COMPANY SNAPSHOT 572 17.11.2 REVENUE ANALYSIS 572 17.11.3 PRODUCT PORTFOLIO 573 17.11.4 RECENT DEVELOPMENT 573 17.12 BIOCARTIS 574 17.12.1 COMPANY SNAPSHOT 574 17.12.2 REVENUE ANALYSIS 574 17.12.3 PRODUCT PORTFOLIO 575 17.12.4 RECENT DEVELOPMENTS 575 17.12.4.1 PARTNERSHIP 575 17.13 BIO-HELIX 576 17.13.1 COMPANY SNAPSHOT 576 17.13.2 PRODUCT PORTFOLIO 576 17.13.3 RECENT DEVELOPMENT 576 17.14 BIO-RAD LABORATORIES, INC 577 17.14.1 COMPANY SNAPSHOT 577 17.14.2 REVENUE ANALYSIS 577 17.14.3 PRODUCT PORTFOLIO 578 17.14.4 RECENT DEVELOPMENTS 578 17.15 EUGENE LABS 579 17.15.1 COMPANY SNAPSHOT 579 17.15.2 PRODUCT PORTFOLIO 579 17.15.3 RECENT DEVELOPMENT 579 17.16 F. HOFFMANN-LA ROCHE LTD 580 17.16.1 COMPANY SNAPSHOT 580 17.16.2 REVENUE ANALYSIS (PARENT COMPANY) 580 17.16.3 PRODUCT PORTFOLIO 581 17.16.4 RECENT DEVELOPMENT 581 17.17 GENES2ME 582 17.17.1 COMPANY SNAPSHOT 582 17.17.2 PRODUCT PORTFOLIO 582 17.17.3 RECENT DEVELOPMENT 582 17.18 MAPMYGENOME 583 17.18.1 COMPANY SNAPSHOT 583 17.18.2 PRODUCT PORTFOLIO 583 17.18.3 RECENT DEVELOPMENT 584 17.19 MEDGENOME 585 17.19.1 COMPANY SNAPSHOT 585 17.19.2 PRODUCT PORTFOLIO 585 17.19.3 RECENT DEVELOPMENT 586 17.20 NATERA, INC 587 17.20.1 COMPANY SNAPSHOT 587 17.20.2 REVENUE ANALYSIS 587 17.20.3 PRODUCT PORTFOLIO 588 17.20.4 RECENT DEVELOPMENT 589 17.21 OTOGENETICS 590 17.21.1 COMPANY SNAPSHOT 590 17.21.2 PRODUCT PORTFOLIO 591 17.21.3 RECENT DEVELOPMENT 591 17.22 PACBIO 592 17.22.1 COMPANY SNAPSHOT 592 17.22.2 REVENUE ANALYSIS 592 17.22.3 PRODUCT PORTFOLIO 593 17.22.4 RECENT DEVELOPMENT 593 17.23 QIAGEN 594 17.23.1 COMPANY SNAPSHOT 594 17.23.2 REVENUE ANALYSIS 594 17.23.3 PRODUCT PORTFOLIO 595 17.23.4 RECENT DEVELOPMENT 595 17.24 SORENSON GENOMICS 596 17.24.1 COMPANY SNAPSHOT 596 17.24.2 PRODUCT PORTFOLIO 596 17.24.3 RECENT DEVELOPMENT 596 18 QUESTIONNAIRE 597 19 RELATED REPORTS 600